Publicaciones en las que colabora con ESTEBAN JESUS MORCILLO SANCHEZ (170)

2021

  1. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor β inducing fibrotic responses

    Mucosal Immunology, Vol. 14, Núm. 2, pp. 377-388

2019

  1. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients

    PLoS ONE, Vol. 14, Núm. 1

  2. MUC1 intracellular bioactivation mediates lung fibrosis

    Thorax, Vol. 75, Núm. 2, pp. 132-142

  3. Mucin 1 deficiency mediates corticosteroid insensitivity in asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 1, pp. 111-121

2018

  1. Fármacos antitusígenos, expectorantes y mucolíticos

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 657-667

  2. Fármacos broncodilatadores y antiinflamatorios en el asma y la enfermedad pulmonar obstructiva crónica

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 667-680

  3. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

    Thorax, Vol. 73, Núm. 6, pp. 519-529

  4. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

    Respiratory Research, Vol. 19, Núm. 1

  5. The JAK2 pathway is activated in idiopathic pulmonary fibrosis

    Respiratory Research, Vol. 19, Núm. 1

2017

  1. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps

    Journal of Allergy and Clinical Immunology, Vol. 139, Núm. 3, pp. 855-862.e13

  2. Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: Current and future evidences

    Current Pharmaceutical Design, Vol. 23, Núm. 14, pp. 2073-2083

2016

  1. Evaluation of mucociliary clearance by three dimension micro-CT-SPECT in Guinea pig: Role of Bitter taste agonists

    PLoS ONE, Vol. 11, Núm. 10

  2. Molecular based drug targets for idiopathic pulmonary fibrosis

    Current Respiratory Medicine Reviews, Vol. 12, Núm. 3, pp. 186-207

  3. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients

    Respiratory Research, Vol. 17, Núm. 1

  4. Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: An ex vivo/in vitro study

    European Respiratory Journal, Vol. 47, Núm. 6, pp. 1737-1749

2015

  1. Pharmacological Assessment of the In Vitro Functional Selectivity of Aclidinium Bromide at M3 and M2 Muscarinic Receptors in Human Tissue

    Pulmonary Therapy, Vol. 1, Núm. 1, pp. 103-107

  2. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

    Respiratory Research, Vol. 16, Núm. 1

  3. Roflumilast prevents the metabolic Effects of bleomycin-induced fibrosis in a murine model

    PLoS ONE, Vol. 10, Núm. 7

2014

  1. Mediadores celulares III: angiotensinas, cininas, citocinas y otros mediadores peptídicos

    Farmacología humana (Elsevier), pp. 336-347

2013

  1. Aclidinium inhibits cigarette smoke-induced lung fibroblast-to- myofibroblast transition

    European Respiratory Journal, Vol. 41, Núm. 6, pp. 1264-1274